Compare BioNTech SE - ADR (BNTX) vs Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? BioNTech SE - ADR trades at $90.35 (market cap $22.86B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $39.15. The key difference: Roundhill S&P 500 0DTE Covered Call Strategy ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | XDTE | |
|---|---|---|
Market Cap | $22.86B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $119.34 | $44.76 |
52-Week Low | $83.89 | $36.00 |
Enterprise Value | $6.53B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
XDTE is trading at $38.91, down 0.74% on the day, with a bearish technical signal from moving averages. The ETF focuses on generating high income through a 0DTE covered call strategy on the S&P 500, offering frequent dividend distributions. Recent news highlights its role in providing daily and weekly income, though some sources note risks associated with potential NAV erosion.
The outlook for XDTE centers on its high-yield income strategy, but investors face significant risks from market volatility and NAV decline. While the fund appeals for tax-efficient weekly payouts, its performance is highly sensitive to S&P 500 movements and options market conditions, warranting caution amid bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Roundhill S&P 500 0DTE Covered Call Strategy ETF
XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →
